Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

A Blinded, Randomized, Placebo-controlled, Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 Tablets Administered Over 14days to Healthy Participants

Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

Inclusion Criteria:

• Participant is a man or woman between the ages of 18 and 60years, inclusive, at the Screening Visit
• Participant is healthy as determined by medical history, physical examination, vital signs, and routine laboratory parameters
• Other inclusions as specified in the protocol

Exclusion Criteria:

• Participant has a prior exposure to ESK-001
• Participant has a history of hypersensitivity to any of the ingredients of ESK-001
• Other exclusions as specified in the protocol